Bladder cancer: a simple model becomes complex
- PMID: 23372425
- PMCID: PMC3401896
- DOI: 10.2174/138920212801619232
Bladder cancer: a simple model becomes complex
Abstract
Bladder cancer is one of the most frequent malignancies in developed countries and it is also characterized by a high number of recurrences. Despite this, several authors in the past reported that only two altered molecular pathways may genetically explain all cases of bladder cancer: one involving the FGFR3 gene, and the other involving the TP53 gene. Mutations in any of these two genes are usually predictive of the malignancy final outcome. This cancer may also be further classified as low-grade tumors, which is always papillary and in most cases superficial, and high-grade tumors, not necessarily papillary and often invasive. This simple way of considering this pathology has strongly changed in the last few years, with the development of genome-wide studies on expression profiling and the discovery of small non-coding RNA affecting gene expression. An easy search in the OMIM (On-line Mendelian Inheritance in Man) database using "bladder cancer" as a query reveals that genes in some way connected to this pathology are approximately 150, and some authors report that altered gene expression (up- or down-regulation) in this disease may involve up to 500 coding sequences for low-grade tumors and up to 2300 for high-grade tumors. In many clinical cases, mutations inside the coding sequences of the above mentioned two genes were not found, but their expression changed; this indicates that also epigenetic modifications may play an important role in its development. Indeed, several reports were published about genome-wide methylation in these neoplastic tissues, and an increasing number of small non-coding RNA are either up- or down-regulated in bladder cancer, indicating that impaired gene expression may also pass through these metabolic pathways. Taken together, these data reveal that bladder cancer is far to be considered a simple model of malignancy. In the present review, we summarize recent progress in the genome-wide analysis of bladder cancer, and analyse non-genetic, genetic and epigenetic factors causing extensive gene mis-regulation in malignant cells.
Keywords: Bladder carcinoma; CIS; FGFR3; MICB; NMIBC; TP53; carcinoma in situ; environmental causes of bladder carcinoma.; epigenetics; small non-coding RNA; urinary tract.
Similar articles
-
Role of Non-Coding RNAs in the Etiology of Bladder Cancer.Genes (Basel). 2017 Nov 22;8(11):339. doi: 10.3390/genes8110339. Genes (Basel). 2017. PMID: 29165379 Free PMC article. Review.
-
Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.Clin Cancer Res. 2005 Nov 1;11(21):7709-19. doi: 10.1158/1078-0432.CCR-05-1130. Clin Cancer Res. 2005. PMID: 16278391
-
Molecular alterations associated with bladder cancer initiation and progression.Scand J Urol Nephrol Suppl. 2008 Sep;(218):154-65. doi: 10.1080/03008880802291915. Scand J Urol Nephrol Suppl. 2008. PMID: 18815930 Review.
-
The evolution of bladder cancer genomics: What have we learned and how can we use it?Urol Oncol. 2018 Jul;36(7):313-320. doi: 10.1016/j.urolonc.2018.02.017. Epub 2018 Mar 21. Urol Oncol. 2018. PMID: 29573965 Review.
-
[Molecular changes in development and progression of urothelial carcinoma].Verh Dtsch Ges Pathol. 2003;87:172-84. Verh Dtsch Ges Pathol. 2003. PMID: 16888910 Review. German.
Cited by
-
WNT/β-catenin signaling in urothelial carcinoma of bladder.World J Nephrol. 2019 Sep 26;8(5):83-94. doi: 10.5527/wjn.v8.i5.83. World J Nephrol. 2019. PMID: 31624709 Free PMC article. Review.
-
Cofilin 1 promotes bladder cancer and is regulated by TCF7L2.Oncotarget. 2017 Sep 6;8(54):92043-92054. doi: 10.18632/oncotarget.20664. eCollection 2017 Nov 3. Oncotarget. 2017. PMID: 29190896 Free PMC article.
-
Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.PLoS One. 2017 Sep 20;12(9):e0184841. doi: 10.1371/journal.pone.0184841. eCollection 2017. PLoS One. 2017. PMID: 28931051 Free PMC article.
-
Identification of key genes associated with bladder cancer using gene expression profiles.Oncol Lett. 2018 Jan;15(1):297-303. doi: 10.3892/ol.2017.7310. Epub 2017 Oct 31. Oncol Lett. 2018. PMID: 29375713 Free PMC article.
-
Prostaglandin receptors EP1-4 as a potential marker for clinical outcome in urothelial bladder cancer.Am J Cancer Res. 2014 Nov 19;4(6):952-62. eCollection 2014. Am J Cancer Res. 2014. PMID: 25520883 Free PMC article.
References
-
- Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J. European Association of Urology (EAU). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur. Urol. 2008;54:303–314. - PubMed
-
- Zhang SW, Ma JH, Li M, Na Y-Q, Chen W-Q. Incidence trends of bladder cancer in cities and counties in China. Chin. J. Urol. 2009;30:673–676.
-
- Hisataki T, Miyao N, Masumori N, Takahashi A, Sasai M, Yanase M, Itoh N, Tsukamoto T. Risk factors for the development of bladder cancer after upper tract urothelial cancer. Urology. 2000;55:663–667. - PubMed
-
- Pelucchi C, Bosetti C, Negri E, Malvezzi M, La Vecchia C. Mechanisms of disease: the epidemiology of bladder cancer. Nat. Clin. Pract. Urol. 2006;3:327–340. - PubMed
-
- Murta-Nascimento C, Schmitz-Drager BJ, Zeegers MP, Steineck G, Kogevinas M, Real FX, Malats N. Epidemiology of urinary bladder cancer: from tumor development to patient’s death. World J. Urol. 2007;25:285–295. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous